US4201768A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for obtaining agents having mitogenic and/or adjuvant properties from Nocardia cells and compositions containing such agents
Assignee: Bpifrance Financement SA
•
Filing: 1977-03-28
•
Granted: 1980-05-06
•
Expires: 1997-03-28
Abstract
Abstract The invention relates to a process for obtaining agents having mitogenic and/or adjuvant properties, from Nocardia cells. According to this process Nocardia whole cells are subjected to a rupturing treatment of their walls within an aqueous medium, particularly distilled water. After the separation of the non-ruptured cells and of the wall fragments of the ruptured cells, mitogenic agents are extracted from the remaining aqueous phase. The fractions obtained are useful as laboratory reagents and for the production of medicamentous compositions in which they are associated with a pharmaceutical vehicle.
Inventors
- 👤 Rita Ciorbaru nee Sfartz
- 👤 Constantin Bona
- 👤 Louis Chedid
- 👤 Edgar Lederer
- 👤 Jean-Francois Petit
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 06:37
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/66; A61K35/74; A61P; A61P37/00; A61P37/02; A61P37/04; A61P43/00
Claims Analysis
Total Claims: 39
Claim 1
Independent Claim
84 words
A method for obtaining a water-soluble agent having mitogenic and/or adjuvant properties in-vivo and in-vitro comprising the steps of: rupturing by physical pressure non-delipidated whole cells of Nocardia within an aqueous medium, forming an aqueous phase and a solid phase comprising cells including ruptured cells, and separating the solid phase and recovering the aqueous phase, which phase is virtually free of cell wall constituents also of the peptidoglycan constituents, but having constituents of the cell cytoplasm, the aqueous phase having adjuvant and/or mitogenic properties.
Claim 2
Independent Claim
84 words
A method for obtaining a water-soluble agent having mitogenic and/or adjuvant properties in-vivo and in-vitro comprising the steps of: rupturing by physical pressure non-delipidated whole cells of Nocardia within an aqueous medium, forming an aqueous phase and a solid phase comprising cells including ruptured cells, and separating the solid phase and recovering the aqueous phase, which phase is virtually free of cell wall constituents also of the peptidoglycan constituents, but having constituents of the cell cytoplasm, the aqueous phase having adjuvant and/or mitogenic properties.
Claim 3
Dependent Claim
27 words
The method of claim 1, further comprising separating a second solid phase comprising cytoplasmic constituents and ribosomes, and a second aqueous phase having mitogenic and/or adjuvant properties.
Claim 4
Dependent Claim
54 words
The method of claim 2, further comprising separating said second aqueous phase essentially free of cytoplasmic constituents and ribosomes into a third solid phase and a third liquid phase comprising non-centrifugable cytosols and having mitogenic and/or adjuvant properties, the third solid phase having ribosomes and mitogenic and/or adjuvant properties and being free of cytosols.
Claim 5
Dependent Claim
14 words
The method of claim 1, wherein the separating step is carried out by centrifugation.
Claim 6
Dependent Claim
14 words
The method of claim 2, wherein the separating step is carried out by centrifugation.
Claim 7
Dependent Claim
14 words
The method of claim 3, wherein the separating step is carried out by ultra-centrifugation.
Claim 8
Dependent Claim
13 words
The method of claim 6, wherein said ultra-centrifugation is at least 100,000 g.
Claim 9
Dependent Claim
31 words
The method of claim 6, wherein prior to said ultra-centrifugation, there is added to said second liquid phase containing residual ribosomes, a precipitation agent which promotes the precipitation of the ribosomes.
Claim 10
Dependent Claim
12 words
The method of claim 8, wherein the precipitation agent is magnesium chloride.
Claim 11
Dependent Claim
13 words
The method of claim 4, wherein said centrifugation is at about 27,400 g.
Claim 12
Dependent Claim
14 words
The method of claim 1, wherein the rupturing step is by physical grinding means.
Claim 13
Dependent Claim
13 words
The method of claim 5, wherein said centrifugation is at about 48,000 g.
Claim 14
Dependent Claim
58 words
The method of claim 1, wherein after said rupturing step and prior to said forming of an aqueous phase and a solid phase, the aqueous composition is subjected to a separation whereby a deposit of unbroken cells is formed and discarded and the aqueous phase produced which contains the insoluble ruptured cells is subjected to said forming step.
Claim 15
Dependent Claim
11 words
The method of claim 13, whereby said separation is by centrifugation.
Claim 16
Dependent Claim
18 words
The method of claim 1, wherein said cells of Nocardia are cells of Nocardia rubra or Nocardia opaca.
Claim 17
Dependent Claim
13 words
The method of claim 15, wherein said cells are cells of Nocardia rubra.
Claim 18
Dependent Claim
13 words
The method of claim 15, wherein said cells are cells of Nocardia opaca.
Claim 19
Dependent Claim
14 words
The method of claim 1, further comprising the step of lyophilizing said aqueous phase.
Claim 20
Dependent Claim
20 words
The method of claim 2, wherein said cells are cells of Nocardia rubra and said second solid phase is mitogenic.
Claim 21
Dependent Claim
13 words
The method of claim 18, wherein said cells are cells of Nocardia rubra.
Claim 22
Dependent Claim
16 words
The method of claim 1, wherein the rupturing of the whole cells is by pressure grinding.
Claim 23
Dependent Claim
19 words
The method of claim 1, wherein the rupturing of the whole cells is by homogenizing within an aqueous medium.
Claim 24
Dependent Claim
26 words
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a water-soluble cytoplasmic extract from non-delipidated Norcardia peptidoglycan containing cells which has mitogenic and/or adjuvant properties.
Claim 25
Dependent Claim
26 words
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a water-soluble cytoplasmic extract from non-delipidated Norcardia peptidoglycan containing cells which has mitogenic and/or adjuvant properties.
Claim 26
Dependent Claim
16 words
The pharmaceutical composition of claim 23 wherein the carrier is an aqueous isotonic sterile injectable solution.
Claim 27
Dependent Claim
11 words
The pharmaceutical composition of claim 23 wherein the carrier is oil-free.
Claim 28
Dependent Claim
19 words
The pharmacetical composition of claim 23, wherein said cells of Nocardia are cells of Nocardia rubra or Nocardia opaca.
Claim 29
Dependent Claim
14 words
The pharmaceutical composition of claim 26, wherein said cells are cells of Nocardia rubra.
Claim 30
Dependent Claim
14 words
The pharmaceutical composition of claim 26, wherein said cells are cells of Nocardia opaca.
Claim 31
Dependent Claim
17 words
The pharmaceutical composition of claim 23, wherein said extract is free of cell wall constituents and peptidoglycans.
Claim 32
Dependent Claim
14 words
The pharmaceutical composition of claim 29, wherein said extract has been subjected to lyophilization.
Claim 33
Dependent Claim
14 words
The pharmaceutical composition of claim 23, wherein said extract comprises cytoplasmic membrane and ribosomes.
Claim 34
Dependent Claim
29 words
The pharmaceutical composition of claim 31, wherein said cells are cells of Nocardia rubra and said composition is mitogenic at doses of 100 μg per kg of the host.
Claim 35
Dependent Claim
24 words
The pharmaceutical composition of claim 23, wherein said composition is mitogenic at a dose of 100 μg of agent per kg of the host.
Claim 36
Dependent Claim
25 words
The pharmacetical composition of claim 23, wherein said composition is an adjuvant at a dose of 100 mg of agent per kg of the host.
Claim 37
Dependent Claim
13 words
The pharmaceutical composition of claim 23, wherein said extract is free of cytosols.
Claim 38
Dependent Claim
35 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mitogenic water-soluble cytoplasmic agent from non-delipidated Nocardia rubra cells comprising cytoplasmic membrane and ribosomes, said agent being free of cell wall constituents and peptidoglycan constituents.
Claim 39
Dependent Claim
35 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mitogenic water-soluble cytoplasmic agent from non-delipidated Nocardia rubra cells comprising cytoplasmic membrane and ribosomes, said agent being free of cell wall constituents and peptidoglycan constituents.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-05-06 | 1983-11-05 | 1984-05-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-05-06 | 1987-11-05 | 1988-05-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-05-06 | 1991-11-05 | 1992-05-06 | $7700.00 | Window Closed / Lapsed |